Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab maintenance after first-line chemotherapy for advanced urothelial cancer
2024-514293-46-00Phase 2Completed
- Sponsor
- SOGUG
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in transitional cell carcinoma (TCC), sponsored by SOGUG. Primary endpoint: Progression-free survival. Started Jun 2024; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-514293-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514293-46-00.